- ALZFORUM | NETWORKING FOR A CURE
By integrating across the discovery lifecycle, C-BRAIN is building collaborative, open-science tools intended to empower researchers and redefine how discovery happens At AD PD 2026, C-BRAIN will showcase its work through a hands-on workshop Alzforum is a member of C-BRAIN Look here for announcements, and follow on LinkedIn
- Databases - ALZFORUM
AlzBiomarker This interactive database captures two decades of research on fluid biomarkers for Alzheimer's disease Curated measurements and related data from peer-reviewed articles are presented, as well as meta-analyses for selected biomarkers This resource, developed in collaboration with Henrik Zetterberg and colleagues at the University of Gothenburg, will be expanded over time as new
- Research Models - ALZFORUM
This database provides information about selected rodent models of neurodegenerative disease, including Alzheimer’s, Parkinson’s, and ALS By summarizing, visualizing, and continuously updating available characterization data, we aim to help researchers learn, compare, and identify models that
- Mission - ALZFORUM
Alzforum is a platform to disseminate the evolving knowledge around basic, translational, and clinical research in the field of AD Alzforum is supported by a team with backgrounds in science journalism, information technology, design, and data science
- Therapeutics - ALZFORUM
AD Target Therapy Types The two tables below organize the therapeutics within this database by therapy type and proposed target type The number of therapeutics within each category is indicated according to the highest phase each therapeutic has achieved in U S clinical trials For example, if a given therapeutic is in both Phase 2 and Phase 3 trials, it is included in the Phase 3 total
- Alzheimers Disease Research Models | ALZFORUM
There is a large ongoing effort to characterize animal models of AD in order to better understand disease pathophysiology as well as to identify models suitable for investigating potential therapeutics By organizing information about the characterization of selected AD models, this resource conveys what is known about each one and facilitates comparison between them Research Models Search
- Roche Spells Out Phase Three Plans for Trontinemab | ALZFORUM
The current Alzheimer’s disease therapeutic antibodies carry a sizable risk of ARIA, especially for APOE4 carriers Researchers believe the future of amyloid immunotherapies lies in targeted brain delivery that bypasses the larger blood vessels prone to this side effect, and several companies are
- Finally, PET Tracers For α-Synuclein Yield Signal in Idiopathic . . .
Robert Mach at the University of Pennsylvania, Philadelphia, agreed “Radiotracers show a hint of working, which is very encouraging,” Mach wrote to Alzforum Mach has been searching for α-synuclein tracers for over a decade Nonetheless, Eberling and Mach noted drawbacks of even these newest tracers For one, they have off-target binding
|